Verastem, Inc.
0LOV.L
London Stock Exchange4.60
USD
+0.21
- -
Verastem, Inc.
0LOV.L
(London Stock Exchange)
Recent
price
4.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Verastem, Inc. (NASDAQ: VSTM; LSE: 0LOV) is a biopharmaceutical company that develops and commercializes precision oncology medicines targeting the RAS/MAPK pathway in cancers; its lead product is the FDA-approved combination therapy of avutometinib, a RAF/MEK clamp inhibitor, plus defactinib, a focal adhesion kinase inhibitor, for KRAS-mutant recurrent low-grade serous ovarian cancer (LGSOC); the company advances a pipeline of novel small molecule inhibitors including VS-7375 and combination strategies for RAS/MAPK-driven tumors such as ovarian, colorectal, non-small cell lung, and pancreatic cancers. Founded in 2010 and headquartered in Needham, Massachusetts, Verastem operates primarily in the United States with a global clinical development footprint through strategic collaborations; it initially focused on cancer stem cells before shifting to RAS/MAPK inhibition, serving patients with high-unmet-need advanced solid tumors. Recent developments include a January 2025 debt refinancing with Oberland Capital providing a pro forma cash position of $128.6 million to extend runway beyond FDA approval and commercialization; a strategic commercialization partnership with IQVIA to support the mid-2025 U.S. launch of avutometinib plus defactinib in recurrent KRAS-mutant LGSOC; an approximately $84 million equity and pre-funded warrant raise in November 2025 to fund commercialization of the AVMAPKI FAKZYNJA co-pack, R&D for pipeline assets, and general corporate purposes; and alliances with Chugai Pharmaceutical and GenFleet Therapeutics to enhance pipeline advancement.